Abstract. Ovarian cancer is the leading cause of mortality among all gynecological malignancies. Drug resistance is a cause of ovarian cancer recurrence and low rate of overall survival. There is a requirement for more effective treatment approaches. Cucurbitacin B (CuB) is an antineoplastic agent derived from traditional Chinese medicinal herbs. Its activity against paclitaxel-resistant human ovarian cancer cells has, however, not yet been established. The purpose of the present study was to investigate the effect and mechanism of CuB on human paclitaxel-resistant ovarian cancer A2780/Taxol cells. Cell viability was evaluated by a cell counting assay, while cell cycle arrest and apoptosis were assessed by microscopy and flow cytometry, and proteins associated with apoptotic pathways and drug resistance were evaluated by western blotting. The present results demonstrated that CuB exerts dose-and time-dependent cytotoxicity against the ovarian cancer A2780 cell line, with half-maximal inhibitory concentration (IC 50 ) values 0.48, 0.25 and 0.21 µM following 24, 48 and 72 h of incubation, respectively. Compared with its sensitive counterpart, A2780, paclitaxel-resistant A2780/Taxol cells had almost identical IC 50 values. Cell cycle analysis demonstrated that treatment with CuB may induce cell cycle arrest at the G 2 /M phase of the cell cycle in the two cell lines. As revealed by Annexin V/propidium iodide-labeled flow cytometry and Hoechst 33258 staining, CuB-induced apoptosis was accompanied by activation of caspase-3 and downregulation of B-cell lymphoma-2. Western blotting demonstrated that CuB may enhance the expression of p53 and p21 in the two cell lines. CuB may also downregulate the expression of P-glycoprotein.
Introduction
Ovarian cancer is the fourth leading cause of cancer-associated mortality in women, with a 5-year survival rate of 25-35% in Western countries (1) . Ovarian cancer often remains undetected until a late stage, and is commonly referred to as a silent killer (2) (3) (4) (5) (6) (7) (8) . Currently, the standard therapy for advanced ovarian cancer includes surgery and systemic chemotherapy (5, (9) (10) (11) . Since 1990, combined platinum-based agents and paclitaxel (Taxol; Bristol-Myers Squibb, New York, NY, USA) have become the first-line chemotherapy for ovarian cancer (12, 13) . Despite a high initial sensitivity to chemotherapy and frequent complete clinical response, the majority of patients with advanced-stage tumors may relapse and gradually develop resistance to the majority of chemotherapeutic drugs (14) (15) (16) . It has not yet been possible to overcome multidrug resistance (MDR) in the clinical settings.
Much effort has been focused on identifying natural compounds that may reverse the MDR phenotype of cancer cells and/or sensitize MDR cancer cells to chemotherapy without undesirable side effects (17) (18) (19) . Traditional Chinese medicines are excellent starting materials, since they are not only a rich source for diverse chemicals, but have been used in humans for thousands of years (20) (21) (22) . Recently, certain natural compounds have been shown to be capable of reversing the drug resistance of ovarian cancer (23) . Abouzeid et al (24) and Sarisozen et al (25) reported that transferring-targeted combination micelles of curcumin and paclitaxel have a clear synergistic effect against paclitaxel-resistant SK-OV-3TR cells. Yang et al (26) demonstrated that tectorigenin may sensitize paclitaxel-resistant human ovarian cancer cells through downregulating the Akt and nuclear factor-κB signaling pathways. Li et al (27) revealed that emodin can sensitize paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Zhou et al (28) reported that silibinin is able to restore paclitaxel sensitivity in paclitaxel-resistant human ovarian carcinoma cells.
Cucurbitacin B (CuB) is a particularly potent member of the triterpenoid family isolated from plants, and has shown anti-proliferative effects on various cancer cells in vitro and in vivo (29) . CuB may induce cell cycle arrest and apoptosis in cancer cells (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) .
In the present study, the inhibitory effect of CuB on the paclitaxel-resistant human ovarian cancer A2780/Taxol cell line and its parental A2780 cell line was assessed. To the best of our knowledge, the present study demonstrated for the first time that CuB inhibits the growth of these two types of cells through induction of cell cycle arrest and apoptosis, by a number of molecular mechanisms. Cell cultures. Ovarian carcinoma A2780 and paclitaxel-resistant A2780 (A2780/Taxol) ovarian carcinoma cell lines were purchased from Nanjing KeyGen Biotech Co., Ltd. (Nanjing, China). Cells were maintained in DMEM (A2780) or RPMI-1640 with 800 ng/ml paclitaxel (A2780/Taxol) supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells were cultured in a humidified atmosphere containing 5% CO 2 at 37˚C. Western blot analysis. Cells (1x10 6 cells/well) seeded onto 6-well plates were treated with 0.0625, 0.125, 0.25, 0.5 and 1 µM CuB or DMSO. The medium was aspirated, and the cells were washed with cold PBS. They were then scraped, washed twice with cold PBS followed by centrifugation at 1,000 x g for 5 min at 4˚C. The pellet was resuspended in lysis buffer supplemented with proteases and phosphatase inhibitors (cat. no. P8340; Sigma-Aldrich; Merck KGaA) and incubated for 1 h at 4˚C. The lysate was collected by centrifugation at 14,000 x g for 40 min at 4˚C, and the supernatant was stored at -20˚C. For western blot analysis, 50 µg proteins were resolved in 8-10% PAGE and transferred to polyvinylidene difluoride membranes. The blot was blocked with a blocking buffer (5% nonfat dry milk/0.1% Tween-20 in TBS) for 1 h at room temperature, and next incubated with appropriate primary antibodies directed against Bcl-2 (1:200), caspase-3 (1:200), p53 (1:1,000), p21 (1:1,000), P-gp (1:200) or β-actin (1:1,000) overnight at 4˚C. The blots were then incubated with horseradish peroxidase-conjugated secondary antibodies (1:1,000-2,000) for 2 h at room temperature and detected with enhanced chemiluminescence, and protein levels were quantified using a Tanon 5200 Chemiluminescent Imaging system (version 1.02; Tanon Science and Technology Co., Ltd., Shanghai, China). β-actin was detected on the same membrane and used as loading control.
Materials and methods

Reagents
Evaluation of multidrug resistance in ovarian cancer cells.
The multidrug resistance of ovarian cancer cells was evaluated by the cell count and P-gp expression. A2780/Taxol and A2780 cells at a density of 8x10 5 cells/well were cultured with docetaxel (0.001, 0.01, 0.1, 1 and 10 µM), doxorubicin (0.01, 0.1, 1, 10 and 100 µM), cisplatin (1, 3, 10, 30 and 100 µM) and gemcitabine (0.01, 0.1, 1, 10 and 100 µM) for 24 h. The viability of the cells was determined using a cell counting assay.
Statistical analysis. All values are expressed as the mean ± standard deviation. Comparison between groups was analyzed by one-way analysis of variance followed by Fisher's least significant difference test using SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA). Two-sided P<0.05 was considered to indicate a statistically significant difference. 05-fold resistance to docetaxel and doxorubicin, respectively. By western blot analysis, the paclitaxel-resistant A2780/Taxol cells also exhibited elevated P-gp protein expression compared with A2780 cells (Fig. 1B) .
Results
Evaluation of MDR in
Inhibition of the viability of A2780/Taxol and A2780 cells by CuB. A2780/Taxol and A2780 cells were treated with 0.0625-1 µM of CuB for 24-72 h, and cell proliferation was measured by counting the number of viable cells. As shown in Fig. 2 , cell proliferation was inhibited by CuB in a doseand time-dependent manner. Similar IC 50 values for CuB in the two cell lines were derived (IC 50 =0.27 µM after 72 h or 0.35 µM after 48 h for A2780/Taxol cells, and IC 50 =0.21 µM after 72 h or 0.25 µM after 48 h for A2780 cells). These results indicated that CuB has a potent anti-proliferative effect on ovarian cancer cells, regardless of whether they had resistance to paclitaxel (Fig. 2) .
Effect of CuB on the cell cycle. A2780/Taxol and A2780 cells were treated with various concentration of CuB for 24 h.
Following PI staining, the population in various phases of the cell cycle was determined by fluorescence-activated cell sorting (FACS) analysis. As shown in Fig. 3A Effect of CuB on cell apoptosis. As shown by FACS, there appeared to be a dose-dependent increase in apoptotic cells in CuB-treated samples compared with the controls. The proportion of apoptotic cells increased from 2.03±0.23 to 11.57±2.03%, and from 1.37±0.44 to 8.77±1.24% in A2780 and A2780/Taxol cells, respectively (P<0.01; Fig. 3B ). In addition, marked morphological changes suggestive of apoptosis, including chromatin condensation, nuclear fragmentation and apoptotic bodies, were observed by Hoechst 33258 staining (Fig. 3C) .
Effect of CuB on the expression of p53 and p21.
The present study investigated whether CuB modulates the expression of p53 and p21 in ovarian cancer cells. As shown in Fig. 4A , CuB treatment could upregulate the expression of p53 and p21 in a dose-dependent manner. Treatment of A2780/Taxol and A2780 cells with 0.25 µM CuB for 24 h significantly upregulated the expression of the p21 (P<0.05), while CuB significantly upregulated the expression of the p53 at 0.5 µM (P<0.05; Fig. 4A ).
Effect of CuB on the expression of Bcl-2 and caspase-3.
Bcl-2 is an important member of the Bcl-2 family of proteins, which regulate cell apoptosis (44) . Bcl-2 is considered an important anti-apoptotic protein and is classified as an oncogene (45) . As shown in Fig. 4A , Bcl-2 is expressed in A2780/Taxol and A2780 cells, and CuB could suppress Bcl-2 expression in a dose-dependent manner. In addition, CuB treatment significantly decreased the intensity of pro-caspase-3 expression (Fig. 4A) .
Effect of CuB on P-gp expression. P-gp is an important protein of the cell membrane, which pumps various foreign substances out of the cell (19) . P-gp is responsible for decreased drug accumulation in MDR cells, and can mediate the development of resistance to anticancer drugs (46) . The present study determined whether CuB downregulates the expression of P-gp in A2780/Taxol cells. As confirmed by western blot analysis, CuB treatment suppressed the expression of P-gp in the A2780/Taxol cell line in a dose-dependent manner (Fig. 4B) .
Discussion
The high mortality of ovarian cancer is usually due to the failure of early detection and lack of effective therapies for late-stage cancers (3, 5) . The standard therapy for advanced ovarian cancer consists of extensive surgical resection followed by combination chemotherapy with paclitaxel/carboplatin (47) . However, such drugs frequently induce resistance (48) . Recently, natural compounds with a high potential and relatively low toxicity have been explored for use as single agents or in combination with a conventional chemotherapeutic agent (24) . For instance, curcumin isolated from curry spice has been demonstrated to potentiate the antitumor activity of various chemotherapeutic agents in a wide range of cancer cells, including drug-resistant ovarian cancer (24, 25, 49, 50) .
CuBs are isolated from various plants, which have been used as folk medicines in countries such as China and India (32) . In recent years, their anti-proliferative effect has been demonstrated on a variety of cancer cells by in vivo and in vitro experiments (32, 35, 42, 51) . The present study confirmed that CuB also has an inhibitory effect on the growth of paclitaxel-resistant A2780/Taxol cells and their parental A2780 cells in a dose-and time-dependent manner. Through a series of experiments, it was demonstrated that CuB treatment resulted in the accumulation of cells at the G 2 /M phase of the cell cycle. CuB could also induce cell apoptosis in a dose-dependent manner. These results indicated that the inhibitory effect of CuB on paclitaxel-resistant A2780/Taxol cells was due to the induction of cell cycle arrest as well as apoptosis.
MDR is the major cause of failure in anticancer treatment (19) . The mechanisms associated with MDR may be classified into two major categories: Pump (P-gp) resistance and non-pump (apoptosis) resistance (52) . The former is mainly caused by overexpression of the P-gp protein, which is capable of reducing the intracellular accumulation of drugs by expelling the drugs outside of the cell (53) . This may lead to resistance to a wide range of anticancer drugs, including doxorubicin, vinblastine, dactinomycin and paclitaxel (54) (55) (56) . Approximately 50% of human cancers overexpress P-gp at levels sufficient to confer MDR (56-59). Through the present study, it was demonstrated that the MDR of A2780/Taxol cells may be in part attributed to overexpression of the P-gp protein, while CuB may significantly inhibit P-gp expression.
The non-pump resistance mechanism is the result of an anti-cell death effect, which mainly improves survival and suppresses apoptosis (60) . Usually, resistance to anticancer drugs is associated with a low propensity to apoptosis (61) . Increased expression of anti-apoptotic proteins, including Bcl-2, has been noted in MDR cells (42, 62, 63) . Therefore, inhibition of Bcl-2 may be a strategy to overcome MDR. The present results demonstrated that CuB induced the apoptosis of A2780/Taxol cells in a dose-dependent manner, which was accompanied by decreased expression of pro-caspase-3 and Bcl-2.
p53 is commonly considered as a tumor-suppressor gene, which can regulate genes involved in apoptosis and may modulate mitochondrial proteins, including Bcl-2, Bcl-2-associated X protein, Bcl-2 homologous antagonist/killer and Bcl-extra large, to promote the release of cytochrome c and apoptosis (64) . It may also induce cell cycle arrest and/or apoptosis in response to cellular stresses, including ionizing radiation, ultraviolet light, growth factor deprivation, reactive oxygen species and DNA damage induced by various cytotoxic agents (65) . There has been accumulating evidence that the status of p53 has a significant impact on drug sensitivity (66) (67) (68) . As confirmed by the present study, CuB treatment increases the protein levels of p53 and p21 in a dose-dependent manner.
In summary, to the best of our knowledge, the present study demonstrated for the first time that CuB can inhibit the growth of paclitaxel-resistant A2780/Taxol cells and induce cell apoptosis through upregulation of p53 and p21, downregulation of Bcl-2, activation of caspase-3 and suppression of P-gp. This compound may therefore provide an adjuvant therapy for the treatment of paclitaxel-resistant ovarian cancer. concentrations of CuB for 24 h, and the protein expression of P-gp was analyzed. Upon CuB treatment, the cells were harvested and processed for western blotting. β-actin was used as an internal control. Immunoblots are representative of three independent experiments. Bcl-2, B-cell lymphoma 2; CuB, cucurbitacin; C, DMSO; P-gp, P-glycoprotein.
